Literature DB >> 32951362

[Pharmacotherapy in older adults with personality disorders: a new area of attention].

Julie E M Schulkens1, Jamila Ibirane1, Sebastiaan P J van Alphen2,3, Sjacko Sobczak1.   

Abstract

BACKGROUND: Pharmacotherapy in older adults with personality disorders (PD) is a new and important area of attention. Nowadays, symptom based pharmacotherapy in older adults with PD is based on multidisciplinary guidelines, which are constructed on research performed in patients up to 50 years of age. There is no specific guideline for older adults with PD. GOAL: Providing a description of patient characteristics: number of comorbid psychiatric disorders, use of medication, including polypharmacy, in older adults (≥ 65 years) with personality disorders.
METHOD: A retrospective cross-sectional patient file study (n = 50) in a clinical center of excellence for older adults with personality disorders (outpatient setting).
RESULTS: . From the file study, it appears that 1) the unspecified/other specified personality disorder and the borderline personality disorder (BPD) occur most frequently, 2) there is a trend (no significant difference) that older adults with BPS use most medication (somatic medication and psychotropics) and 3) there is a trend (no significant difference) that polypharmacy is the most prevalent amongst older adults with BPD.
CONCLUSION: The use of medication in certain subgroups of older adults with PD tends to be high. Further research is necessary to optimize pharmacotherapy in older adults with PD.

Entities:  

Keywords:  Personality disorders; Pharmacotherapy; Polypharmacy

Mesh:

Year:  2019        PMID: 32951362     DOI: 10.36613/tgg.1875-6832/2019.03.01

Source DB:  PubMed          Journal:  Tijdschr Gerontol Geriatr        ISSN: 0167-9228


  1 in total

1.  Remission of Suicidal Ideation in Emotionally Unstable Personality Disorder with Flupenthixol.

Authors:  Daniel J Chivers; Mohammed Shaffiullah
Journal:  Case Rep Psychiatry       Date:  2022-01-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.